OL-CD19-GDT CAR‑T for relapsed or refractory systemic sclerosis and primary Sjögren's syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open‑label, single‑arm Phase 1 trial administering OL‑CD19‑GDT CAR‑T cells to adults with relapsed or refractory systemic sclerosis (SSc) or primary Sjögren's syndrome (pSS). Eligible participants must meet specific classification criteria (2013 ACR/EULAR for SSc or 2016 ACR/EULAR for pSS), have active disease (e.g., mRSS >10 for SSc or ESSDAI ≥5 for pSS), and adequate organ function. Patients undergo lymphodepletion followed by a single infusion of the investigational CAR‑T product with planned pharmacokinetic and safety monitoring and serial assessments of disease activity and organ function. The primary focus is safety and tolerability with secondary data collected on pharmacokinetics and preliminary clinical activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18-65 years old
* ECOG 0-2
* Adequate organ function
* Females of childbearing potential (FCBP) must have a negative pregnancy test at screening and must agree to use a highly effective contraceptive method starting from the time of lymphodepletion and for 2 years after dosing of the IMP
* SSc specific:

  a)Fulfilling the 2013 ACR/EULAR classification criteria of SSc; b) mRSS score \>10; c) at least one vital organ involvement besides the skin; d)relapsed or refractory to at least one immunosuppressant or biologic.
* pSS specfic: a)Fulling the 2016 EULAR/ACR classification critieria for pSS; b) anti-Ro/anti-SSA antibody positive; c) ESSDAI score ≥5 ; d)relapsed or refractory to at least one immunosuppressant or biologic.

Exclusion Criteria:

* Active uncontrolled infection
* Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load
* Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load
* HIV antibody positive
* Syphilis antibody positive
* Active tuberculosis, untreated or inadequately treated latent tuberculosis infection (LTBI)
* History of serious infection within 3 months prior to screening (defined as requiring hospitalization or intravenous antimicrobial therapy), or history of oral antimicrobial therapy within 1 month prior to screening (e.g., viral infections, opportunistic infections, including but not limited to severe cytomegalovirus or herpes virus infections)
* Congenital long QT syndrome or a corrected QTcF interval of ≥480 ms at screening (unless secondary to pacemaker or bundle branch block)
* Uncontrolled hypertension (blood pressure ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes or other endocrine diseases, severe chronic pulmonary disease, or other serious medical condition which is likely to significantly impair the patient's ability to tolerate the study treatment
* history of organ transplant
* Pregnancy or lactating women
* Use of any other experimental medication within 4 weeks or 5 half-lives prior to start of study drug
* Use of biologics within 10 weeks, stem cell transplant within 6 months prior to the start of study drug
* Prior CAR-T treatment
* Received live or attenuated vaccine within 4 weeks of Cycle 1 Day 1
* Presence of other autoimmune or auto-inflammatory diseases that may affect study assessments, such as rheumatoid arthritis, gout, or active fibromyalgia syndrome.
* Limited to patients diagnosed with SSc: at risk for scleroderma renal crisis; SSc-associated gastric antral vascular ectasia; Severe gastrointestinal involvement leading to malabsorption or intestinal failure
* Limited to patients diagnosed with pSS: primary biliary cholangitis

Where it's running

• Beijing GoBroad Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Shaocong Miao
• Email: miaosc@gobroadhealthcare.com
• Phone: 86+18831006667

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCMA/CD70-directed CAR-T for children with hard-to-treat rheumatic diseases

  This trial will try a BCMA/CD70-directed CAR-T therapy in children aged 5 and older whose rheumatic diseases have not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT07184450

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease

  This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07507201

• Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases

  This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07305116

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.